Importance Phase 3 trials of successful antiamyloid therapies in Alzheimer disease (AD)
have demonstrated improved clinical efficacy in people with less severe disease. Plasma …

Growing evidence supports the use of plasma levels of tau phosphorylated at threonine 181,
amyloid-β, neurofilament light and glial fibrillary acidic protein as promising biomarkers for …

Background Recent advances in disease-modifying treatments highlight the need for
accurately identifying individuals in early Alzheimer's disease (AD) stages and for …

With the development of testing technologies, bloodbased biomarkers for Alzheimer's
disease (AD) such as amyloid-β (Aβ), phosphorylated tau (P-tau), and neurofilament light …

Background and objective Phosphorylated tau (p-tau) 217 has recently received attention
because it seems more reliable than other p-tau variants for identifying Alzheimer's disease …

INTRODUCTION For routine clinical implementation of Alzheimer's disease (AD) plasma
biomarkers, fully automated random‐access platforms are crucial to ensure reproducible …

Background Previous studies reported the value of blood-based biomarkers in predicting
Alzheimer disease (AD) progression among individuals with different disease stages …

To evaluate the clinical importance of cerebrospinal fluid (CSF) phosphorylated tau 181 (p-
tau 181) in mild cognitive impairment (MCI), Alzheimer's disease (AD) and other dementias …

Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established
biomarker of Alzheimer's disease (AD), reflecting abnormal tau metabolism in the brain …

Staging amyloid-beta (Aβ) pathophysiology according to the intensity of neurodegeneration
could identify individuals at risk for cognitive decline in Alzheimer's disease (AD). In blood …